US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
Omvoh is now approved in the United States for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults. Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. Lilly says that Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval.
The FDA decision was based on positive results from the Phase 3 VIVID-1 study of Omvoh in adults with moderately to severely active Crohn's disease who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine and methotrexate) and/or biologics (TNF blockers, integrin receptor antagonists).
Langhua Pharmaceutical passes US FDA's on-site inspection
PTC Therapeutics announces opinion regarding Translarna's (ataluren) European renewal authorisation
Soleno Therapeutics selects PANTHERx Rare as specialty pharmacy for VYKAT XR distribution
Neurim Pharmaceuticals' Slenyto approved for insomnia in children with ADHD
Intelligent Bio Solutions strengthens IP with sixth US patent ahead of 2025 market entry
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
Nyxoah receives FDA Approvable Letter for Genio system
Palatin Technologies' PL7737 granted US FDA orphan drug designation
Benuvia Operations receives five-year contract from NIDA
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA